INTRODUCTION {#sec1-1}
============

Depression is a chronic and recurrent disorder and up to 16% of adult population experience at least one period of depression through their life.\[[@ref1][@ref2]\] Due to the high prevalence of depression in adolescents,\[[@ref3]\] the World Health Organization has predicted that by 2020 depression will become the second major disease in the world.\[[@ref4]\] Therefore, the discovery and the development of more effective therapies is of significant importance for alleviating this problem. Despite the recognition of different types of treatment for depression, a group of patients does not respond to the treatment that is called drug-resistant major depression (DRMD). Electroconvulsive therapy (ECT) is one of the oldest therapies available for the treatment of resistant depression and is still the most effective (at a rate of 50--70%) method.\[[@ref5]\] Performing ECT without anesthesia could have several side effects such as a headache, confusion, delirium, fracture of vertebrae and ribs, muscle pain, nausea, vomiting, and memory loss.\[[@ref6][@ref7]\] Intravenous anesthetics applied for this purpose include methohexital, propofol, midazolam, remifentanil, lidocaine, sodium thiopental, and ketamine. Considering the crucial role of seizure duration on therapeutic response in patients treated with ECT, drugs such as ketamine, sodium thiopental that has more and better impact on increasing the seizure duration are of more attention and usage.\[[@ref8][@ref9]\] However, there is a controversy in finding of the positive effects of anesthetic drugs, especially sodium thiopental and ketamine. In addition, more conducted studies have a retrospective design or prospective studies with low sample size. Therefore, the aim of the current study was to compare the effect of anesthesia with ketamine or sodium thiopental during ECT in patients with DRMD.

MATERIALS AND METHODS {#sec1-2}
=====================

A single-blind simple randomized clinical trial were enrolled 160 patients with DRMD, who is referring to Psychiatric Center of Amir Kabir Hospital, Arak, Iran. Patients who were between 20 and 60-year-old, affecting to DRMD according to Diagnostic and Statistical Manual of Mental Disorders-text revised-DSM-IV-TR diagnostic criteria with confirmation of psychiatrist, and without any contraindications for ECT included to the study. Moreover, patients who are affect to any type of cardiovascular and cerebrovascular disease, high intracranial pressure, respiratory tract diseases, serious bone fractures, glaucoma, high intraocular pressure, uncontrolled hypertension, arterial aneurysm or cerebrovascular malformation, previous history of epilepsy, alcohol, and drug abuse with history of sensitivity to anesthetic agents, pregnancy, other psychiatric disorders, dementia were excluded. In addition, study subjects did not performing ECT in the last 3 months. The demographic information and past medical history was registered. In addition, hemodynamic parameters were measured before and after ECT and were recorded in the patients' checklist. All patients were nil per os (NPO) for at least 6--8 h before ECT After recruitment of patients and taking informed consent, random allocation applied by block randomization method. Group A received ketamine 0.8 mg/kg and Group B received sodium thiopental 1--1.5 mg/kg intravenously before ECT and were anesthetized. Then ECT was performed for 30--90 s 3 times a week. Ultimately, 8 sessions of ECT was performed. After finishing ECT sessions, the patient\'s recovery time and postanesthesia complications were checked and recorded in the 1^st^ h by an anesthesiologist after 2^nd^, 4^th^, 6^th^, and 8^th^ sessions of ECT.

Hamilton depression rating scale (HDRS-17 items) was used for depression assessment. The scores of this scale ranged from 0 to 52.\[[@ref10][@ref11]\] Acquiring scores between 0 and 7 classified as normal and subjects who give scores 20 or higher than categorized as depression and higher scores had been showed the severity of depressive symptoms are moderate, severe, or very severe.\[[@ref12]\] Validity and reliability of this scale was reported between 0.91 and 0.94\[[@ref13]\] and 0.74,\[[@ref14]\] respectively. HDRS was used before the onset of trial and after the end of sessions 2, 4, 6, and 8 ECT. Participants filled the informed consent and ethics committee of Arak University of medical sciences approved the trial protocol. Moreover, this trial is registered in Iranian register clinical trial center by IRCT2015013012642N13 number. Chi-square test, trend test, and analysis of variance for repeated measure were used for statistical analysis. Data analyzed in SPSS (IBM Corp, Armonk, NY) software and a significant level considered in 0.05.

RESULTS {#sec1-3}
=======

The mean and standard deviation of systolic and diastolic blood pressure was 120.6 ± 13.7 and 75.2 ± 8.9 mm/g, respectively. 53.5% (86/160) of participants were female, and this rate was equal in two groups (*P* \> 0.05). In addition, no difference observed in age groups, education level, gender, blood pressure, history of previous ECT, duration of current major depression, age of onset major depression, cigar smoking, and birth in rural area at baseline measurement \[[Table 1](#T1){ref-type="table"}\].

###### 

The baseline measurement of two studied groups based on demographic and depression characteristics

  Variables                              Ketamine     Sodium thiopental   *P*
  -------------------------------------- ------------ ------------------- -------
  Age groups                                                              
   20-29                                 23 (29.5)    21 (28)             0.425
   30-39                                 28 (35.9)    19 (25.3)           
   40-49                                 14 (17.9)    18 (24)             
   50-59                                 13 (16.7)    17 (22.7)           
  Female sex                             43 (53.8)    43 (53.8)           0.563
  Education level                                                         
   Under diploma                         32 (40)      35 (43.8)           0.743
   Diploma                               28 (35)      21 (26.2)           
   College                               20 (25)      24 (30)             
  Lived in rural area                    18 (23.1)    17 (21.2)           0.466
  Cigar smoking                          20 (25)      27 (33.8)           0.271
  Age of onset major depression                                           
   Lower 20                              17 (21.8)    16 (20)             0.969
   20-29                                 29 (37.2)    31 (38.8)           
   30-39                                 20 (25.6)    19 (23.8)           
   40 and higher                         15 (15.4)    14 (17.5)           
  Duration of current major depression                                    
   Lower 2 years                         23 (28.8)    25 (31.2)           0.879
   2-2.9                                 15 (18.8)    18 (22.5)           
   3-3.9                                 18 (22.5)    16 (20)             
   4 and higher                          24 (30)      21 (26.2)           
  No history of the previous ECT         62 (77.5)    50 (62.5)           0.116
  Diastolic blood pressure               75.8±9.1     74.6±8.7            0.374
  Systolic blood pressure                121.6±14.6   119.6±12.8          0.400

ECT: Electroconvulsive therapy

As showed in [Table 2](#T2){ref-type="table"}, there was a significant difference in side effects of ECT including to a headache, nausea, and fear with the illusion of awakenings between groups in most of the sessions (*P* \< 0.05). Pain in the injection site and short-term delirium were not significantly different between groups at all sessions (*P* \> 0.05). In addition, long-term delirium was not significantly different in most of the sessions (except in 6^th^ sessions) (*P* \> 0.05). Moreover, the findings depicted in [Table 3](#T3){ref-type="table"} showed that the systolic and diastolic blood pressure have statistically significant difference in all sessions between ketamine and sodium thiopental after ECT, but there was not observe significant trend in each medication. Both medications had a significant impact on the amount of electrical energy usage and seizure duration overall. The difference in energy usage and seizure duration was not significant between two medication (*P* \> 0.05) except in session 4 for seizure duration (*P* = 0.002). Moreover, the overall trend of energy usage and seizure duration was significant in two groups (*P* \< 0.05). There was an increasing significant trend in energy usage and a decreasing trend in seizure duration in both medications. However, the complication is lower in sodium thiopental group than ketamine group.

###### 

Comparing the rate of complication including headache, nausea, pain in injection site, fear with illusion of awakenings, short and long-term delirium after ECT between two groups

  Complication                        Session   Ketamine    Sodium thiopental   *P*
  ----------------------------------- --------- ----------- ------------------- -------
  Headache                            1         51 (63.8)   37 (46.2)           0.019
                                      2         54 (67.5)   38 (47.5)           0.008
                                      4         51 (63.8)   36 (45)             0.013
                                      6         48 (60)     32 (40)             0.009
                                      8         49 (61.2)   29 (36.2)           0.001
  Trend test                                                                    
   Nausea                             1         37 (46.2)   25 (31.2)           0.037
                                      2         32 (40)     24 (30)             0.123
                                      4         29 (36.2)   16 (20)             0.017
                                      6         26 (32.5)   11 (13.8)           0.004
                                      8         29 (36.2)   12 (15)             0.002
   Pain in injection site             1         11 (13)     5 (6.2)             0.093
                                      2         5 (6.2)     5 (6.2)             0.627
                                      4         4 (5)       2 (2.5)             0.341
                                      6         5 (6.2)     1 (1.2)             0.105
                                      8         5 (6.2)     1 (1.2)             0.105
   Fear with illusion of awakenings   1         48 (60)     33 (41.2)           0.013
                                      2         42 (52.5)   32 (40)             0.077
                                      4         32 (40)     18 (22.5)           0.013
                                      6         32 (40)     18 (22.5)           0.013
                                      8         31 (38.8)   14 (17.5)           0.002
   Short-term delirium                1         69 (86.2)   66 (82.5)           0.332
                                      2         74 (88.8)   66 (82.5)           0.184
                                      4         68 (85)     66 (82.5)           0.415
                                      6         64 (80)     68 (85)             0.267
                                      8         66 (82.5)   66 (82.5)           0.582
   Long-term delirium                 1         52 (65)     49 (61.2)           0.372
                                      2         50 (62.5)   46 (57.5)           0.314
                                      4         48 (60)     40 (50)             0.133
                                      6         51 (63.8)   37 (46.2)           0.019
                                      8         49 (61.2)   38 (47.5)           0.056

ECT: Electroconvulsive therapy

###### 

Comparing the rate of complication including systolic and diastolic blood pressure, the rate of used energy and seizer duration after ECT between two groups

  Session                     Ketamine     Sodium thiopental   *P*
  --------------------------- ------------ ------------------- ---------
  Systolic blood pressure                                      
   1                          184.4±26.1   168.3±19.2          \<0.001
   2                          189.5±26.3   171.2±19.1          \<0.001
   4                          185.7±20.7   169.1±22.1          \<0.001
   6                          189.1±22.1   170±20.9            \<0.001
   8                          187.2±20     171±17.7            \<0.001
  Repeated measure*P* value   0.416        0.834               
  Diastolic blood pressure                                     
   1                          99.5±16.4    91.1±16.2           0.001
   2                          99.9±13.1    91.6±14.2           \<0.001
   4                          100.1±12.2   92±15.6             \<0.001
   6                          100.1±13.5   90.4±14.1           \<0.001
   8                          99.9±13.3    92.2±16             0.001
  Repeated measure*P* value   0.846        0.790               
  Duration of seizure                                          
   1                          37.9±10.2    35.2±12.4           0.141
   2                          36.2±10.8    34.9±8.8            0.393
   4                          35.7±8.6     31.8±7.2            0.002
   6                          35.4±10.3    33.6±9.6            0.262
   8                          34.8±7.9     29.8±7.3            0.057
  Repeated measure*P* value   0.023        0.020               
  Used energy                                                  
   1                          43±8.8       42.2±9.4            0.591
   2                          44.9±8.2     45.1±8.6            0.844
   4                          49.7±10.1    50.6±11             0.627
   6                          52.2±12.4    55.5±13.8           0.113
   8                          53.4±11.8    56±14.6             0.219
  Repeated measure*P* value   \<0.001      \<0.001             

ECT: Electroconvulsive therapy

According to the [Table 4](#T4){ref-type="table"}, the Mauchly\'s test of sphericity was significant, and the HDSR score was showed a significant decreasing trend in both groups that indicates the good effect of medications. (*P* \< 0.001) Also, this trend was significantly different between two groups (*P* = 0.049) \[[Figure 1](#F1){ref-type="fig"}\]. In the other hand, the effect of ketamine was more rapid in the recovery from major depression. Nevertheless, the difference in mean depression score in each session was not significant except in session 8 (*P* = 0.2).

###### 

Comparing the mean±SD of HDRS score between ketamine and sodium thiopental groups after ECT

  Session      Ketamine     Sodium thiopental   *P*\*
  ------------ ------------ ------------------- -------
  HDRS score                                    
   1           29.82±7.3    28.86±7.6           0.442
   2           29.34±7.45   21.89±6.8           0.279
   4           15.43±6.16   17.73±8.33          0.061
   6           12.06±6.41   13.44±8.48          0.270
   8           8.32±5.17    10.53±7.87          0.047

\**T*-test. SD: Standard deviation, HDRS: Hamilton depression rating scale, ECT: Electroconvulsive therapy

![The trend of decreasing in Hamilton depression rating scale score between ketamine and sodium thiopental groups after electroconvulsive therapy](ACA-18-486-g001){#F1}

DISCUSSION {#sec1-4}
==========

The findings in our study showed that the depression score have been decreased after every ECT session in two anesthetic agents. Although the side effects were more common in ketamine group but the groups were not significantly different based on pain in injection site, short- and long-term delirium, duration of seizure, and usage of energy. Ketamine was more effective in decreasing the depression score and increasing systolic and diastolic blood pressure than sodium thiopental. In addition, both groups had significant decreasing trend on seizure duration at different sessions. Nevertheless, the seizure duration was higher in ketamine group. Barkhori *et al*. showed that ketamine had significant effect in seizure duration, decrease in depression score, and rapid effect in comparison to sodium thiopental,\[[@ref15]\] which is consistent with our study. The same results were obtained in Ibrahim *et al*. study.\[[@ref16]\] In addition, different studies have demonstrated the rapid impact of ketamine on reduction of depression scores.\[[@ref17][@ref18][@ref19][@ref20][@ref21]\] Yaraghi *et al*. reported that ketamine will increase blood pressure, seizure duration, and recovery time significantly compared to sodium thiopental.\[[@ref22]\] Although, this study is similar to our results but ketamine intervention was related with shorter seizure duration. Nevertheless, another study compared the anesthetic induction effect of thiopental and ketamine in incidence of emergence agitation after pediatric surgery and showed that these two drugs have similar results.\[[@ref23]\] However, based on the acquired results some complication such as headache, nausea, and fear with illusion of awakenings was higher in ketamine group. Nevertheless, other side effects were not statistically significant between two groups. Therefore, due to higher impact of ketamine versus sodium thiopental on decreasing of HDRS and recovery of major depression patients, ketamine is more appropriate for anesthesia in ECT in depressive patients which need to anesthesia in ECT. Another study suggested that due to rapid onset and maintenance of improvement after IV ketamine is effective in decreasing suicidality in acutely suicidal depressed patients.\[[@ref24]\]

CONCLUSION {#sec1-5}
==========

Finally, because of more increase in seizure duration in ECT session, we recommend ketamine for inducing anesthesia before ECT in DRMD patients. Also, recommend that future studies compare the effect of ketamine with other anesthetics suitable for ECT in DRMD cases. Because many studies have shown that depressed patients suffer from cognitive deficits, such as impaired memory, it is better that future studies evaluate the effectiveness of ketamine and sodium thiopental on cognitive deficits such as memory impairment.
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